Oncodistinct Network News Today

Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors to be presented by partner AstraZeneca Preclinical

Upcoming Panel Discussion, Hosted by Xtalks on Precision Oncology: An Era that Calls for a New Model for Conducting Clinical Trials? Share Article During this discussion, the featured speakers will examine lessons learnt from the clinical development of targeted therapies such as immunotherapeutic agents, and current methodological challenges for new drug development in the precision oncology era. They will provide insights into a novel approach to conduct clinical research in the precision onc...